文献速递脑血管病

晚时间窗M2段大脑中动脉闭塞血管内治疗:CLEAR研究分析

Endovascular Therapy for Late-Window M2-Segment Middle Cerebral Artery Occlusion: Analysis of the CLEAR Study.
PubMed 文献 · Stroke · 2025-05-22

这项多国队列研究纳入5098例患者中的496例晚时间窗(6-24小时)M2闭塞患者,其中394例(79.4%)接受血管内治疗(EVT),102例(20.6%)接受药物治疗(MM)。经逆概率治疗加权调整后,EVT与MM在90天改良Rankin量表序贯移位(OR 1.39,95%CI 0.92-2.12)、功能独立率(OR 1.72,95%CI 0.93-3.15)、症状性颅内出血风险(OR 3.46,95%CI 0.50-23.92)及90天死亡率(OR 1.11,95%CI 0.66-1.87)上均无统计学差异。

要点

  • 晚时间窗M2闭塞患者中,EVT与MM的90天改良Rankin量表序贯移位无显著差异(OR 1.39,95%CI 0.92-2.12)。
  • EVT与MM的功能独立率(mRS 0-2)无显著差异(OR 1.72,95%CI 0.93-3.15)。
  • 症状性颅内出血风险(OR 3.46,95%CI 0.50-23.92)和90天死亡率(OR 1.11,95%CI 0.66-1.87)在两组间无统计学差异。

核心结论

  • 在6-24小时时间窗的M2闭塞患者中,EVT与MM在残疾结局或症状性颅内出血风险方面无差异。

研究设计与样本

  • 多国队列研究,在10个国家66个中心开展(2014年1月至2022年5月),纳入连续晚时间窗M2闭塞、基线NIHSS≥5、病前mRS≤2且接受EVT或单纯MM的患者。
  • 共筛查5098例患者,496例符合纳入标准(中位年龄74岁[IQR 62-81],基线NIHSS 12[IQR 8-17]),其中394例(79.4%)接受EVT,102例(20.6%)接受MM。

主要发现

  • 逆概率治疗加权调整分析显示,EVT与MM相比,90天改良Rankin量表序贯移位无有利差异(OR 1.39,95%CI 0.92-2.12)。
  • 功能独立率(mRS 0-2)在EVT与MM之间无差异(OR 1.72,95%CI 0.93-3.15)。
  • 症状性颅内出血风险(OR 3.46,95%CI 0.50-23.92)和90天死亡率(OR 1.11,95%CI 0.66-1.87)在两组间无统计学差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is uncertainty about whether patients with M2 occlusion benefit from endovascular therapy (EVT) in the late (6-24-hour) time window. We evaluated the clinical outcomes of patients with M2 occlusion selected for EVT compared with those who received medical management (MM) in the late window. METHODS: This multinational cohort study was conducted at 66 sites across 10 countries (January 2014 to May 2022). We included consecutive patients with late-window stroke due to M2 occlusion, baseline National Institutes of Health Stroke Scale score of ≥5, and premorbid modified Rankin Scale score of ≤2 who received EVT or MM alone. The primary end point was 90-day ordinal shift in the modified Rankin Scale score. Safety end points were symptomatic intracranial hemorrhage and 90-day mortality. Differences in outcomes were determined using inverse probability of treatment weighting-adjusted logistic regression models. RESULTS: Among 5098 patients, 496 met inclusion criteria (median [interquartile range] age, 74 years [62-81 years]; baseline National Institutes of Health Stroke Scale score, 12 [8-17]), of whom 394 (79.4%) received EVT and 102 (20.6%) MM. In inverse probability of treatment weighting adjusted analyses, there was no favorable 90-day ordinal modified Rankin Scale shift (odds ratio, 1.39 [95% CI, 0.92-2.12]) and no difference of functional independence rates (modified Rankin Scale score of 0-2; odds ratio, 1.72 [95% CI, 0.93-3.15]) with EVT compared with MM. Moreover, symptomatic intracranial hemorrhage risk (odds ratio, 3.46 [95% CI, 0.50-23.92]) and 90-day mortality (odds ratio, 1.11 [95% CI, 0.66-1.87]) were not statistically different between treatment groups. CONCLUSIONS: In patients with M2 occlusion in the 6- to 24-hour time window, there was no difference in disability outcomes or symptomatic intracranial hemorrhage risk between patients treated with EVT compared with MM. Results of ongoing randomized trials will provide further insight. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04096248.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Winzer S, Kaiser DPO, Qureshi MM, et al. Endovascular Therapy for Late-Window M2-Segment Middle Cerebral Artery Occlusion: Analysis of the CLEAR Study. Stroke. 2025. PMID: 40405459. doi:10.1161/STROKEAHA.124.048840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。